IT IS WELL KNOWN that the anticholinesterase drugs neostigmine and pyridostigmine may produce prolonged inhibition of plasma cholinesterase in addition to inhibition of acetylcholinesterase.
Before the induction of anesthesia, cefazolin (1 g) was given intravenously. Standard of care monitors were applied, including electrocardiogram (leads II, V) and electroencephalogram. The patient's preoperative blood pressure was 164/65 mm Hg and the pulse rate was 60/min. General anesthesia was induced with fentanyl (100 g), sodium thiopental (400 mg), and succinylcholine (140 mg). After successful endotracheal intubation, anesthesia was maintained with isoflurane (0.4% to 0.6%) and air and oxygen. Neuromuscular blockade was monitored at the ulnar nerve, using a MicroStimulator (Sun Med, Clearwater, Fla). After return of neuromuscular function was documented by sustained 100 Hz tetanus and full train of four (TOF) twitch response (12 minutes after administration of succinylcholine), rocuronium (30 mg) was given and the surgical procedure proceeded without difficulty. Electroencephalogram remained symmetrical in both cerebral hemispheres throughout the procedure. At the completion of surgery, 2 hours after induction of anesthesia, the patient had 2 out of 4 twitches on a TOF stimulation and 100 Hz tetanus fade. Neuromuscular blockade was reversed with glycopyrrolate (0.6 mg) and neostigmine (4.2 mg). The patient had good grip, followed commands, and was able to sustain head lift for 5 seconds. Return of neuromuscular function was shown by sustained 100 Hz tetanus and full TOF twitch response. The patient was extubated and taken to the postanesthesia care unit in stable condition.
The patient was returned to the operating room 2 hours after completion of the initial operation for emergency evacuation of a surgical hematoma. At the time of induction, the patient was alert and oriented, vital signs were stable, oxygen saturation was >95% on oxygen at 2 L/min by nasal cannula, and respirations were unlabored. Standard monitors were applied, and preoxygenation was done with 100% oxygen by face mask. A rapid sequence induction was done with etomidate (28 mg) and succinylcholine (140 mg). The trachea was slightly deviated to the left but was easily intubated. Anesthesia was maintained with isoflurane (0.4% to 0.5%) and oxygen. The operation proceeded without complication and was completed 45 minutes after induction of anesthesia. Neuromuscular blockade was not monitored before extubation because the patient had received a single dose of succinylcholine. After attaining spontaneous ventilation and moving purposefully, the patient was extubated. He immediately appeared tachypneic and agitated and was given 100% oxygen by face mask. Ventilation was assisted and 40 mg of doxepram was administered, without improvement in respiratory effort. Twitch response to TOF stimulation displayed a twitch height ratio of <0.7 and 100 Hz tetanus fade. Glycopyrrolate (1.0 mg) and neostigmine (2.5 mg) were administered to treat a presumed diagnosis of phase II blockade from succinylcholine. The patient's respiratory function did not improve and a second dose of neostigmine (2.5 mg) was given. The patient then became apneic immediately, and his ventilation was controlled by face mask in oxygen. He was reintubated without complication using no medications. Arterial blood gas values drawn immediately after reintubation were pH 7.21, PCO2 64 mm Hg, PO2 113 mm Hg, HCO3 25 mEq/L, and oxygen saturation 97%. The serum potassium value was 4.6 mEq/L, calcium value 0.96 mg/dL, hematocrit value 31%, and glucose value 170 mg/dL. The temperature was 37.1°C (98.8°F). The patient was taken to the postanesthesia care unit (PACU) and mechanically ventilated. Thirty minutes after entering the PACU (2 hours after the intubating dose of succinylcholine and 1 hour after neostigmine reversal), blood samples were sent for dibucaine and plasma cholinesterase measurements, which were 76% (normal, 80% to 88%) and 1.36 U/mL (normal, 7 to 19 U/mL), respectively. The patient was extubated after showing sustained 100 Hz tetanus, full TOF twitch response, sustained head lift, and the ability to follow commands (2 hours after arriving in the PACU and 3 hours after receiving the intubating dose of succinylcholine). Twenty-four hours after extubation, dibucaine and plasma cholinesterase levels were 86% and 10.48 U/mL, respectively. The remainder of the postoperative course was uneventful, and the patient was discharged home on postoperative day 2.
DISCUSSION
Succinylcholine, a depolarizing neuromuscular blocking drug, is administered during induction of general anesthesia to facilitate endotracheal intubation. This short-acting agent has a rapid onset (30 to 60 seconds) and a short duration of action (3 to 5 minutes). Termination of neuromuscular effects of succinylcholine occurs by plasma cholinesterase (pseudocholinesterase) hydrolysis. Plasma cholinesterase hydrolyzes the majority of a dose of succinylcholine before it reaches the neuromuscular junction, thereby influencing the duration of neuromuscular blockade. Prolongation of the neuromuscular effects of succinylcholine can occur when a single large dose or repeated doses of succinylcholine are administered, when there is a deficiency of plasma cholinesterase, or when other drugs such as anticholinesterase drugs inhibit plasma cholinesterase activity. 3 Several studies suggest that the action of succinylcholine should not be prolonged by more than 30 minutes in the presence of neostigmine anticholinesterase reversal of neuromuscular blockade. 2, 4 Neostigmine is an anticholinesterase drug that binds to the catalytic site of the acetylcholinesterase enzyme via a covalent bond, which is a carbamate-enzyme bond that inhibits acetylcholinesterase activity for many minutes. 5 Neostigmine is capable of inhibiting both acetylcholinesterase and plasma cholinesterase activity. The elimination of neostigmine, like pyridostigmine and edrophonium, occurs by renal excretion. The elimination half-life of neostigmine is 80 minutes in patients with normal renal function, 105 minutes in renal transplant patients, and 180 minutes in patients with renal failure. 6 Bishop and Hornbein 7 have reported two cases in which a prolonged effect of succinylcholine was seen after neostigmine and pyridostigmine administration in patients with frank renal failure. Our case shows that this problem can also occur in patients with renal insufficiency.
The differential diagnosis for postoperative respiratory insufficiency in this patient with residual neuromuscular blockade included phase II blockade from succinylcholine, markedly decreased or abnormal plasma cholinesterase levels, and prolonged effect of succinylcholine in the presence of an anticholinesterase agent. (A cerebrovascular insult was not likely, since the patient had awakened, followed commands, and shown no focal deficits. Inadvertent administration of nondepolarizing neuromuscular blockers was also ruled out.) Twitch height ratio in response to TOF stimulation was <0.7 and 100 Hz tetanus demonstrated fade. A phase II block from succinylcholine was considered an explanation, since two doses (2.3 mg/kg each) of succinylcholine were given over a 4-hour period to this elderly patient. However, the response to anticholinesterase therapy was unexpected as the patient progressed from weakness to frank paralysis. This unexpected response does not support phase II blockade as a likely diagnosis. Neuromuscular weakness from phase II blockade should improve with anticholinesterase therapy.
To rule out abnormal plasma cholinesterase levels and/or phenotype, blood samples were drawn in the PACU after the second operation, during the time the patient was totally ventilator-dependent. Although the dibucaine level was normal, plasma cholinesterase activity levels were reported as critically low. If genetic or metabolic factors were responsible for this low activity level, a prolonged effect from the first dose of succinylcholine would have been seen during the initial operation. Also, plasma cholinesterase levels measured 24 hours later were normal.
The most likely explanation for the prolonged neuromuscular blockade after succinylcholine administration in this patient is the accumulation of previously given anticholinesterase inhibitor. Two hours had passed between the administration of the anticholinesterase agent (neostigmine) and succinylcholine, and 3 hours had passed between the administration of neostigmine and extubation after the second operation. It is likely that the presence of coexisting renal insufficiency prolonged the half-life of neostigmine to the point that covalently bonded plasma cholinesterase was present when the second dose of succinylcholine was given. This explanation is supported by the exacerbation in muscle weakness seen when treating the patient for phase II block with neostigmine. Whatever plasma cholinesterase remained was inhibited by the neostigmine administered to treat the presumptive phase II block.
It is not surprising that plasma cholinesterase levels, which were artificially lowered because of neostigmine binding, were normal 24 hours later. Furthermore, plasma cholinesterase levels measured 1 hour after neostigmine administration might be expected to be low. Should the plasma cholinesterase levels have been 13% (1.36 U/mL) of the patient's normal level (10.48 U/mL)? Mirakhur et al 1 reported return of 80% of serum cholinesterase levels 1 hour after neostigmine administration in patients with normal renal function. In our patient, whose serum creatinine value was 2.6 mg/dL, it is possible that accumulation of anticholinesterase drug occurred after 2 doses of neostigmine (0.07 mg/kg and 0.08 mg/kg) had been administered 3 hours apart. Accumulation of anticholinesterase drug may have produced a plasma cholinesterase level that was 13% of the patient's normal level. It is difficult to speculate what the plasma cholinesterase levels were at the end of the second operation and before the treatment of the presumptive phase II block with neostigmine. What is important is that this patient with chronic renal insufficiency, as evidenced by a serum creatinine value of 2.6 mg/dL, showed a profound effect from a single dose of neostigmine (0.07 mg/kg) administered during his first operation. This patient displayed a prolonged block from succinylcholine, 3 hours after neostigmine administration.
In summar y, we believe this is the first reported case that shows a prolonged effect of neostigmine due to coexisting chronic renal insufficiency. Patients with renal insufficiency, like patients with renal failure, are at greater risk than normal patients for having prolonged succinylcholine blockade if they have recently (within several hours) received anticholinesterase reversal of neuromuscular blockade.
